Informed Consent for Research

Informed Consent for Research

Informed consent for research is an ongoing process in which a prospective participant receives understandable, relevant information, has a genuine opportunity to ask questions and decide freely, and agrees to the research activities that apply to them. A signed form can document that process, but the signature alone does not establish understanding or voluntariness. The content and legal requirements depend on the study, setting and jurisdiction; research ethics review remains essential.

What a participant needs to decide

The invitation should distinguish research from ordinary clinical care and explain what participation changes. A person needs enough information to judge burdens, risks, potential benefits, alternatives and uses of information without being promised a personal benefit that the study cannot support. The information should be presented in a way the particular population can understand, including appropriate language, accessibility and time to consider.

Decision topic	What the discussion should make clear	Common failure
Purpose and procedures	Why the study is being done, what will happen, which activities are research and how long participation lasts.	Describing a research intervention as routine care.
Possible effects	Foreseeable risks, burdens, uncertain benefits and relevant alternatives.	Suggesting that assignment to an intervention guarantees improvement.
Choice and withdrawal	Participation is voluntary, with the applicable right to refuse or withdraw and the practical consequences explained.	Implying that declining will jeopardize usual care or benefits.
Data and samples	What information or material is collected, who may use or receive it, safeguards, future uses and relevant limits to confidentiality.	Treating broad language about “data use” as unlimited permission.
Costs, payments and contact	Participant costs or compensation, arrangements for research-related harm when applicable, and who can answer study or rights questions.	Hiding possible out-of-pocket costs or pressure created by incentives.

These topics are a teaching framework, not a substitute for the full elements required by the governing ethics committee and law. In the United States, the Common Rule calls for a concise presentation of key information at the start of consent in covered research, followed by the applicable required details. The 2024 Declaration of Helsinki emphasizes plain language, comprehension, voluntariness and the ability to refuse or withdraw without reprisal.

Consent is a sequence, not a document event

The research team should approach a person in circumstances that allow independent consideration, explain the study, invite questions, check comprehension and document the decision according to the approved procedure. A teach-back question can reveal whether a prospective participant has understood randomization, optional procedures or the distinction between treatment and research. A person can still decline after understanding everything; comprehension is not a test they must “pass” to accept the researcher's preferred answer.

1. Confirm the approved approach. Identify the eligible population, approved information materials, consent personnel, language support and any required permissions before recruitment.
2. Explain the decision. Present the key information and study-specific risks, benefits, procedures, alternatives and data uses in accessible terms.
3. Allow a real choice. Give an opportunity to ask questions and consider participation without coercion or undue influence, especially where a clinician, employer or service provider has authority over the person.
4. Record the outcome. Document consent, refusal, representative permission or an approved waiver or alteration as required by the applicable protocol and rules.
5. Continue the conversation. Communicate material new information, seek renewed agreement where required, honor the approved withdrawal process and keep the record of what version was used.

Written or electronic documentation can be required, but obtaining consent and documenting consent are different requirements. Under the U.S. Common Rule, an institutional review board (IRB) can in specified circumstances waive the requirement for a signed consent document while still requiring a consent conversation. This is distinct from an IRB-approved waiver or alteration of the requirement to obtain consent itself. The precise route should be determined under the governing regime, not inferred from the study being “low risk” or from researchers' convenience.

Capacity, dependence and inclusion

Decision-making capacity is specific to a decision and time; it should not be assumed absent merely because someone has a diagnosis, disability or language need. Provide suitable communication support and assess understanding in context. Where a person cannot give legally effective consent, the authorized representative and additional protections are governed by the applicable framework, and the person's own wishes or dissent still matter.

Children and others unable to provide legally effective consent may require permission from a parent or legally authorized representative and age- or capacity-appropriate assent. Assent is meaningful agreement, not simply silence or failure to object; the exact rules and exceptions are jurisdiction- and protocol-specific. The 2024 Declaration of Helsinki calls for assent when an incapable participant can express it and for respecting dissent. Researchers must also recognize that dependent relationships, financial hardship, limited treatment options or fear of losing services can compromise an apparently voluntary “yes.”

Ethical safeguards should make research accessible without targeting people because they are easy to recruit or excluding them reflexively. Translation, interpretation, accessible formats and independent consent personnel may be needed. Community engagement can improve study design and trust, but a community representative's view does not replace an individual's consent when that person is capable of deciding.

Records, registries and secondary use

Health economic and outcomes research often uses trial data, electronic health records, claims, registries or stored samples. The fact that care data already exist does not automatically authorize their use for every research purpose. The legal classification of identifiable and coded data, privacy obligations, data-sharing permissions and ethics review need to be assessed for the particular project and location.

For example, an investigator proposes to analyze identifiable past hospital records to compare costs and outcomes. If contacting every patient is impracticable, the investigator may submit a justified request for an IRB or research ethics committee to consider a waiver or alteration under the applicable criteria. In U.S. Common Rule research, the general waiver criteria include no more than minimal risk, impracticability without the waiver, no adverse effect on rights and welfare, an additional impracticability condition for use of identifiable information or specimens, and provision of pertinent information afterward whenever appropriate. The investigator does not grant the waiver to themselves. An IRB's determination should be recorded; data minimization and security remain relevant even when consent is waived.

Broad consent, specific consent, opt-in, opt-out, a waiver of documentation and a waiver of consent are not interchangeable. The U.S. Common Rule's broad-consent option has a defined scope for storage, maintenance and secondary research use of identifiable private information or biospecimens and additional conditions. Declining a request for broad consent can constrain a later waiver under that particular regulatory route. Other jurisdictions use different legal bases and procedures, so a U.S. example should not be copied as a universal rule.

How consent affects economic and statistical evidence

Consent is an ethical obligation and can also shape the evidence base. Who is approached, who agrees and who remains in a study can change the observed distribution of costs, quality of life and outcomes. If those with severe illness or poor access are less likely to participate, a complete-case analysis may be unrepresentative even with accurate calculations. Withdrawal can also create missing follow-up information; the approved consent language and data governance determine what may be retained or collected afterward.

Analysts should record recruitment and consent flow, compare participants with the eligible population when lawful data allow, and explain missingness, selection and generalizability limits. Statistical adjustment may help under its assumptions but cannot automatically recover information from people never observed. The possibility of selection bias does not itself justify bypassing consent; an ethics body must weigh any request for a waiver against the applicable criteria and participant protections.

Privacy and consent are related but distinct. A lawful basis to process data, an ethics approval, a data-use agreement and a participant's research consent can each serve different roles, and the existence of one does not automatically satisfy the others. Withdrawal of consent to future participation may not undo analyses already completed or publication of aggregate results; the actual limits must be explained accurately in the study materials and managed under the governing rules.

Review and reporting checks

Report the applicable ethics review, approved consent procedure and version, how capacity and language needs were handled, who obtained consent, and how refusals and withdrawals were respected. For secondary-data research, identify the review determination and data safeguards without implying that a blank consent field is evidence of an approved waiver. Methods reporting should make the participant flow and resulting selection limits visible.

• Check clarity. A participant should be able to explain in their own words what is research, what is optional and what happens if they decline.
• Check voluntariness. Recruitment setting, authority relationships and incentives should not compromise free choice.
• Check scope. Consent for a clinical visit, a trial intervention, future use of samples and linkage of administrative data may cover different activities.
• Check authorization. Any waiver or alteration must come from the competent review body under the applicable framework and be documented before relying on it.
• Check continuity. Material protocol changes, new uses or new risk information may require an updated participant discussion or additional review.

Sources and further reading

The World Medical Association's 2024 Declaration of Helsinki states international ethical principles for voluntary participation, information, capacity and research using identifiable data. The current U.S. Common Rule provision at 45 CFR 46.116 specifies informed-consent requirements and defined waiver routes for research to which it applies. The HHS Office for Human Research Protections consent guidance distinguishes consent processes and documentation. The CIOMS international ethical guidelines discuss consent, secondary use and ethical review across settings. The hospital-record scenario is illustrative, not an approval determination for any actual study.